Inclusion Criteria:  18 of age or older, regardless of gender; Patients with NYHA II-IV, LVEF less than 40%; Levels of NT-proBNP more than 450 pg/ml Willing to participate in this study and sign an informed consent, and receive follow-up contact for at least 6 months.  Exclusion Criteria:  Onset of acute myocardial infarction within the last 1 month; Had cardiac surgery or onset of cerebrovascular accident within the last 6 months; Plan to have cardiac transplantation or CRT, or already having CRT therapy; Females with pregnancy or plan to have pregnancy; Have participate in any other clinical trial within the last 3 months; Severe neurological disorders (Alzheimer's disease, progressive stage of Parkinson's syndrome), disabilities of lower limbs or deaf-mute; had a history of tumour, or precancerous lesions confirmed by pathological tests (ductal carcinoma in situ, cervical dysplasia, etc.); had malignant tumours (by physical examinations, X-ray, type-B ultrasonic imaging or other methods), or had hyperplastic glands or adenoma which possess endocrine activity and affect cardiac or endocrine functions (pheochromocytoma, goitre, etc.); The subjects who refuse to comply with the items of the research protocol; The subjects who are not available to fulfil the follow-up plan (due to project management or other reasons), according to the judgement of researchers.